KRAS and lung adenocarcinoma: Alterations in the RTK/RAS/PI(3)K pathway were mutually exclusive in urothelial carcinomas.[29] The co‐occurrence EGFR and KRAS mutations in lung adenocarcinoma causes cell death.[30] Hence, molecular targeting therapy against EGFR may not be an efficacious UTUC treatment.